Weill Cornell Medicine has been awarded a five-year, $9 million Program Project Grant from NCI to better understand how and why patients with an aggressive and incurable form of lymphoma initially respond to treatment, only to relapse over time.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe